Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews


Print Page Follow BioNews on Twitter BioNews RSS feed

Like the Progress Educational Trust on Facebook



King's College London - Health: More than a medical matter





Pair of gene-targeted melanoma drugs show promise in late-stage clinical trials

11 June 2012

By Tamara Hirsch

Appeared in BioNews 660

Two drugs targeting advanced melanoma linked to a mutation in the BRAF gene are more effective than current chemotherapy at slowing the progress of the skin cancer, clinical trial results indicate.

Dabrafenib and trametinib were both produced by pharmaceuticals company GSK and may represent a further advance in personalised medicine for cancer, where drugs are targeted specifically against the genetic underpinnings of the disease. Results from the final series of clinical trials before the drugs could become widely available (phase III trials) were presented at the Annual Meeting of the American Society of Clinical Oncology in Chicago last week.

The BRAF mutation has been identified in around half of all cases of melanoma, and patients were selected for eligibility based on the BRAF mutation status of their cancer in both trials.

Patients given dabrafenib lived for 5.1 months before their disease worsened (a measure called progression-free survival, or PFS) compared to 2.7 months with standard chemotherapy. In a separate trial, trametinib showed a PFS of 4.8 months compared to 1.5 months following chemotherapy.

For a long time melanoma was considered nearly untreatable. Dr Caroline Robert, head of Dermatology at the Institute Gustave Roussy in Paris, and lead investigator of the trametinib study told the New York Times, that now, thanks to recent advances, 'In melanoma, we are living something incredible'.

Roche currently market a BRAF inhibitor which improves survival in advanced melanoma but can result in a less severe form of skin cancer known as cutaneous squamous cell carcinoma. These tumours can be removed surgically but are clearly undesirable and trametinib does not appear to induce them. The drug works by blocking a protein called MEK, which is just downstream of BRAF in the chain of signals that prompt tumor growth.

The trametinib trial enlisted 322 patients and the survival rate was 81 percent in the trametinib group compared to 67 percent in the chemotherapy group after 6 months. The drug's clear benefits meant that patients in the chemotherapy cohort were later allowed to crossover to receive trametinib therapy. Meanwhile the dabrafenib study enrolled 250 patients and the drug, which is a BRAF inhibitor, reduced the risk of disease progression or death by 70 percent.

Dr Rafael Amado, head of oncology research and development at GSK said that trametinib was 'the first MEK inhibitor to demonstrate clinical benefit in a late phase melanoma trial'.

He added: 'We are planning regulatory submissions for dabrafenib and trametinib as single agent therapies and have recently started a phase III programme to further investigate the effect of the combination in this disease'.

 

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

30 July 2012 - by Dr Rosie Morley 
The European Medicines Agency has recommended European Union market approval for a gene therapy, Glybera, to treat patients with severe cases of a rare genetic condition called lipoprotein lipase deficiency... [Read More]

28 May 2012 - by James Brooks 
A drug that mimics broken strands of DNA and pushes treatment-resistant cancer cells to autodestruct has produced encouraging results in a first clinical trial. The medicine, DT01, is the forerunner for a new class of drug developed by researchers at the Institut Curie in Paris... [Read More]
14 March 2011 - by Dr Sarah Spain 
An international collaborative team, including Cancer Research UK scientists from the University of Dundee, has uncovered the genetic cause of a rare type of skin cancer. The condition called Ferguson-Smith disease, is also known as multiple self-healing squamous epithelioma (MSSE)... [Read More]
14 April 2009 - by Dr Will Fletcher 
Up to 70 per cent of cases of malignant melanoma, the most deadly form of skin cancer, may be triggered by a mutation in the BRAF gene caused by ageing and over-exposure to the sun. Details of the new findings were published in the journal Cancer Cell... [Read More]
30 March 2009 - by Dr Rebecca Robey 
US scientists have found a link between a variant in the gene MDM2, called MDM2 SNP309, and the occurrence of melanoma in younger women. The study, published in the journal Clinical Cancer Research, found that MDM2 SNP309 was significantly more common in women who were diagnosed with... [Read More]
04 September 2006 - by Dr Jess Buxton 
By Dr Jess Buxton: US scientists have reported the first successful use of gene therapy to treat cancer. Two men with advanced melanoma are now free of the disease, after taking part in a trial based at the National Cancer Institute in Bethesda, Maryland. The new technique involves injecting patients... [Read More]

HAVE YOUR SAY
Be the first to have your say.

You need to Login or Register to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions

 


 

- click here to enquire about using this story.

Printer Friendly Page

Published by the Progress Educational Trust
RISK ASSESSMENT:
BREAST CANCER, PREDICTION AND SCREENING
FREE public event in central London, 6.30pm on Thursday 8 May 2014 - find out more HERE

DataLabel Supplying Printed Labels To The UK For Over 15 Years

ANNIVERSARY APPEAL
Please donate HERE, so that the Progress Educational Trust can continue throughout 2014 (and beyond) while keeping BioNews FREE for you to read

The Progress Educational Trust was shortlisted for the Charity Times Awards 2011

Advertise your products and services HERE - click for further details

Good Fundraising Code

Become a Friend of PET HERE, and give the Progress Educational Trust a regular donation